Brief: Cyteir Therapeutics Reports Fourth Quarter Results
23/03/2023 20:12
March 23 (Reuters) - Cyteir Therapeutics Inc CYT.O :
* CYTEIR THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR
2022
FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
* CYTEIR THERAPEUTICS INC Q4 LOSS PER SHARE $0.25
* CYTEIR THERAPEUTICS INC - PROJECTED CASH RUNWAY INTO 2026
Source text for Eikon: ID:nBw50ZfQka
Further company coverage: CYT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cyteir Therapeutics
See all newsBrief: Cyteir Announces Timeline For Voluntarily Delisting From Nasdaq
Brief: Cyteir Therapeutics Timothy Romberger Resigned From Board & All Of Its Committees
Brief: Ongoing Results From A Dose Expansion Cohort Of Cyt-0851 In Combination With Capecitabine In Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity And Generally Well Tolerated Safety Profile
Brief: Cyteir Therapeutics Announces Discontinuation Of Cyt-0851 Development Program And Planned Liquidation And Dissolution
Brief: Cyteir Says Preliminary Ongoing Results With CYT-0851 In Combination With Capecitabine Or Gemcitabine In Advanced Solid Tumors Show Early Clinical Activity And Generally Well Tolerated Safety Profile